Example: confidence
New Zealand Data Sheet - Medsafe
New Zealand Data Sheet Page 1 of 7 DUKORAL®. Vibrio cholerae. and enterotoxigenic . Escherichia coli. vaccine . Name of the Medicine . Vaccine containing heat inactivated Vibrio cholerae O1 Inaba classic strain, formalin inactivated Vibrio cholerae O1 Inaba El Tor strain, heat inactivated Vibrio cholerae O1 Ogawa classic strain, formalin …
Tags:
Information
Domain:
Source:
Link to this page:
Documents from same domain
ADVANTAN Presentation Uses - Medsafe
www.medsafe.govt.nzADVANTAN® Data Sheet Page 1 of 9 ADVANTAN® Methylprednisolone aceponate 0.1% ointment/cream . Presentation 1 g cream or ointment contains 1 mg (0.1%) methylprednisolone aceponate.
LOXALATE 1. Product Name - Medsafe Home Page
www.medsafe.govt.nzPage 5of 21 at risk, such as the elderly, or patients with cirrhosis, or if used in combination with other medications which may cause hyponatraemia.
DATA SHEET 1 CLEXANE AND CLEXANE FORTE ... - …
www.medsafe.govt.nzNew Zealand Data Sheet June 2017 . clexane-clexane-forte-ccdsv13-dsv18-16jun17 Page 2 . 100 mg injection enoxaparin sodium 100mg (equivalent to …
SEPTANEST Articaine hydrochloride 4% with …
www.medsafe.govt.nzSEPTANEST Articaine hydrochloride 4% with adrenaline 1:100,000 Injection for local and regional dental anaesthesia DESCRIPTION SEPTANEST is a sterile aqueous solution that contains articaine hydrochloride 4% (40 mg/mL) with adrenaline acid tartrate in a 1:100,000 strength.
BOOSTRIX - Medsafe Home Page
www.medsafe.govt.nz1 BOOSTRIX®. Combined diphtheria, tetanus, acellular pertussis (dTpa) vaccine . CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET? This leaflet answers some of the common questions about BOOSTRIX vaccine.
NEW ZEALAND DATA SHEET - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET Cymevene ® DS 170831 2 of 26 Caution: Cymevene must only be administered by IV infusion over 1 hour, preferably via a
Edition Draft - Medsafe
www.medsafe.govt.nzPart 4, Ed Draft Page 2 of 9 Section 1: Good Manufacturing Practice Documentation 1.1. When is GMP Documentation Required? Medsafe requires evidence of Good Manufacturing Practice (GMP) compliance for
Data Sheet 1 PRODUCT NAME 2 QUALITATIVE AND …
www.medsafe.govt.nzNew Zealand Data Sheet 31 July 2017 Lantus – insulin glargine lantus-ccdsv19-dsv11-31jul17 Page 1 Data Sheet 1 PRODUCT NAME Lantus 100 IU/mL solution for injection in 10 …
NEW ZEALAND DATA SHEET MESTINON® - Medsafe
www.medsafe.govt.nzNEW ZEALAND DATA SHEET MESTINON® MESTINON Page 4 of 8 As the severity of myasthenia gravis often fluctuates considerably, particular care is required to
DATA SHEET PREDNISONE - Medsafe
www.medsafe.govt.nz• Epilepsy and/or seizure disorder • Peptic ulceration • Previous steroid myopathy • Tuberculosis • Patients with myasthenia gravis receiving anticholinesterase therapy since
Related documents
Biosimilars, Oxidative Damage, and Unwanted …
www.bioprocessintl.com28 BioProcess International 11(6)s Ju n e 2013 Supplement B i o s i m i l a r s Technical Biosimilars, Oxidative Damage, and Unwanted Immunogenicity A Review by Edward T. Maggio C oncerns about the economic viability of biosimilars center
FIRST DRAFT Guideline on clinical evaluation of …
www.ema.europa.euGuideline on clinical evaluation of vaccines EMEA/CHMP/VWP/164653/05 Rev. 1 Page 6/21 165 4. Immunogenicity 166 4.1. Characterisation of the immune response
Biosimilars in the EU
www.ema.europa.euInformation guide for healthcare professionals Biosimilars in the EU Prepared jointly by the European Medicines Agency and the European Commission
HIGHLIGHTS OF PRESCRIBING INFORMATION …
www.merck.comHIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use RECOMBIVAX HB safely and effectively. See full prescribing
Guidelines on Clinical Evaluation of Vaccines: …
www.who.int1 2 3 WHO/DRAFT/27 January 2016 4 ENGLISH ONLY 5 6 7 Guidelines on Clinical Evaluation of Vaccines: Regulatory Expectations 8 Proposed revision of WHO TRS 924, Annex 1 9 10 NOTE: 11 12 This document has been prepared for the purpose of inviting comments and suggestions on the proposals 13 contained therein, which will …
Annex 4 - WHO
www.who.int153 Annex 4 Recommendations to assure the quality, safety and efficacy of influenza vaccines (human, live attenuated) for intranasal administration
Morbidity and Mortality Weekly Report
www.cdc.govMorbidity and Mortality Weekly Report Recommendations and Reports June 22, 2007 / Vol. 56 / No. RR-4 INSIDE: Continuing Education Examination depardepardepartment of health and human servicesvicesvices